Skip to main content
OpenTrials

Clinical trial condition

Recurrence

Explore clinical trials studying Recurrence. Study availability and eligibility vary by location and protocol.

2,359 public trials 538 recruiting studies
Refine in advanced search Browse all conditions

Recurrence trial results

Recruiting

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

NCT05798897

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Hodgkin Disease, +18 more
Locations
  • City of Hope Duarte, California, United States
  • University of Colorado Aurora, Colorado, United States
  • Colorado Blood Cancer Institute (Sarah Cannon) Denver, Colorado, United States
  • University of Kansas Medical Center Kansas City, Kansas, United States
View Trial Details
Recruiting

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

NCT06846606

Conditions
Bone Marrow Diseases, Disease Attributes, Hematologic Diseases, +16 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • H Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
  • Roswell Park Comprehensive Cancer Center Buffalo, New York, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details
Recruiting

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06297226

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 214) Los Angeles, California, United States
View all 52 locations
View Trial Details
Recruiting

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

NCT06806033

Conditions
Cytokine Release Syndrome, Disease Attributes, Hemic and Lymphatic Diseases, +17 more
Locations
  • Alaska Oncology & Hematology, LLC Anchorage, Alaska, United States
  • Community Cancer Institute (CCI) Clovis, California, United States
  • Providence Medical Foundation Fullerton, California, United States
  • Los Angeles Cancer Network Glendale, California, United States
View all 53 locations
View Trial Details
Recruiting

A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

NCT06634589

Conditions
B-cell Lymphoma, B-cell Malignancy, Disease Attributes, +15 more
Locations
  • Mayo Clinic Phoenix Phoenix, Arizona, United States
  • University of Southern California Norris Comprehensive Los Angeles, California, United States
  • Mayo Clinic Jacksonville Jacksonville, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 49 locations
View Trial Details
Recruiting

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

NCT01356290

Conditions
ATRT Recurrent, Disease Attributes, Ependymoma, +16 more
Locations
  • Ann & Robert H. Lurie Children's Hospital of Chicago Chicago, Illinois, United States
  • Dana-Farber Cancer Institute and Boston Children's Hospital Boston, Massachusetts, United States
  • Helen DeVos Children's Hospital Grand Rapids, Michigan, United States
  • Dell Children's Medical Group SFC-HEM/ONC Austin, Texas, United States
View all 22 locations
View Trial Details

Related conditions